Menu

Category

All
  • ASH 2021
  • Clinical trials
  • PODCASTS
  • UPDATE CLL
  • UPDATE CMV INFECTIONS
  • UPDATE SCD

Disorder

All
  • chronic lymphocytic leukemia
  • CLL
  • cytomegalovirus infections
  • Leukaemia
  • multiple myeloma
  • myelofybrosis
  • Sickle Cell Disease

Year

All
  • 2020
  • 2021
  • 2024
SUBSCRIBE TO BJH HEMATALKS SERIES

Podcasts

September 2024

Exploring Second-Generation BTK Inhibitors in Chronic Lymphocytic Leukemia (CLL)

Dr. Adam Kittai (Icahn School of Medicine, Mount Sinai, New York)

Dr. Kittai is an Associate Professor at the Icahn School of Medicine at Mount Sinai in New York, NY where he is the Assistant Director of Lymphoma Clinical Research and CLL Clinical Research Leader. His clinical and research focus is on Chronic Lymphocytic Leukemia, Richter Transformation and related disorders. He is the primary investigator of multiple investigator-initiated trials exploring the use of small molecule inhibitors with novel designs and deploying cellular therapies for CLL and Richter transformation.

This HematoTalk is brought to you by the publisher of the Belgian Journal of Hematology (BJH) in partnership with AstraZeneca.

NS ID 4610-Revision date 08/2024-WEB Local code 1506

All podcasts

January 2024
PODCASTS 

Dr Deeren discusses the latest update in the management of patients with Paroxysmal Nocturnal Hemoglobinuria including the place of the new long acting C5 inhibitor ravulizumab in the treatment algorithm
Dr. Dries Deeren (AZ Delta, Roeselare)
September 2023

Prof. Paolo Ghia discusses the results of a matching-adjusted indirect comparison of acalabrutinib versus zanubrutinib in relapsed or refractory chronic lymphocytic leukemia
Prof. Paolo Ghia (Università Vita Salute San Raffaele, Italy)
January 2022
ASH 2021 

Time-limited venetoclax and ibrutinib for patients with R/R CLL and undetectable MRD
Prof. Carsten Niemann, Department of Clinical Medicine, University of Copenhagen, Denmark
January 2022
ASH 2021 

Talha Munir about ibrutinib plus venetoclax vs chlorambucil plus obinutuzumab for CLL patients
Dr. Talha Munir, Leeds Teaching Hospital NHS Trust, Leeds, United Kingdom
September 2021
Clinical trials 

Prof. Susan O’Brien about the value of acalabrutinib in CLL
Prof. Susan O’Brien, University of California Irvine, United States
August 2021
UPDATE CLL 

Dr. Davide Rossi: “How to optimize the first-line treatment for patients with CLL?”
Dr. Davide Rossi, Deputy Head of the Division of Hematology of the Oncology Institute of Southern Switzerland IOSI and Head of the Laboratory of Experimental Hematology at the Institute of Oncology Research IOR in Bellinzona, Switzerland
June 2021
UPDATE SCD 

Dr. Ann Van de Velde about Sickle Cell Disease; more than sickled red blood cells
Dr. Ann Van de Velde, Head of the Haematology Clinic, University Hospital of Antwerp
October 2020
UPDATE CMV INFECTIONS 

The burden of CMV infection and real-life data of CMV prophylaxis
Dr. Anke Verlinden, Hematologist at University Hospital Antwerp
September 2020

Long term exposure to momelotinib in JAK inhibitor naïve and previously JAK inhibitor treated intermediate or high risk myelofibrosis patients
Top